- Home
- KPTI vs RCON Comparison
KPTI vs RCON Comparison
Compare KPTI & RCON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPTI
- RCON
- Stock Information
- Founded
- KPTI 2008
- RCON 2007
- Country
- KPTI United States
- RCON China
- Employees
- KPTI N/A
- RCON N/A
- Industry
- KPTI Biotechnology: Pharmaceutical Preparations
- RCON Oilfield Services/Equipment
- Sector
- KPTI Health Care
- RCON Energy
- Exchange
- KPTI Nasdaq
- RCON Nasdaq
- Market Cap
- KPTI 44.5M
- RCON 45.3M
- IPO Year
- KPTI 2013
- RCON 2009
- Fundamental
- Price
- KPTI $4.20
- RCON $2.08
- Analyst Decision
- KPTI Buy
- RCON
- Analyst Count
- KPTI 6
- RCON 0
- Target Price
- KPTI $48.50
- RCON N/A
- AVG Volume (30 Days)
- KPTI 86.5K
- RCON 19.3K
- Earning Date
- KPTI 05-12-2025
- RCON 06-27-2025
- Dividend Yield
- KPTI N/A
- RCON N/A
- EPS Growth
- KPTI N/A
- RCON N/A
- EPS
- KPTI N/A
- RCON N/A
- Revenue
- KPTI $142,126,000.00
- RCON $8,996,572.00
- Revenue This Year
- KPTI $2.34
- RCON N/A
- Revenue Next Year
- KPTI $13.81
- RCON $12.17
- P/E Ratio
- KPTI N/A
- RCON N/A
- Revenue Growth
- KPTI 1.19
- RCON N/A
- 52 Week Low
- KPTI $3.51
- RCON $1.32
- 52 Week High
- KPTI $17.40
- RCON $3.70
- Technical
- Relative Strength Index (RSI)
- KPTI 35.16
- RCON 52.90
- Support Level
- KPTI $4.33
- RCON $1.90
- Resistance Level
- KPTI $4.65
- RCON $2.39
- Average True Range (ATR)
- KPTI 0.47
- RCON 0.18
- MACD
- KPTI -0.12
- RCON 0.02
- Stochastic Oscillator
- KPTI 8.95
- RCON 42.13
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
About RCON Recon Technology Ltd.
Recon Technology Ltd is an oilfield service company. The company is engaged in providing oilfield automation products, specialized equipment for oil and gas production and transportation, chemicals, and field services to petroleum companies mainly in the People's Republic of China (PRC). It has four reportable operating segments: Automation Product and Software, Equipment and Accessories, Platform outsourcing services, and Oilfield Environmental Protection. The majority of the firm's revenue comes from the Automation Product and Software segment which provides products and services like pumping unit controllers, natural gas flow computer systems, wireless dynamometers and wireless pressure gauges, and an oilfield monitor and data acquisition system among others.